TFF Pharmaceuticals, Inc. (TFFP) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/15/21
TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/15/21
TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma PatientsGlobeNewsWire • 11/08/21
TFF Pharmaceuticals to Participate in the 12th Annual Jefferies London Healthcare Conference 2021GlobeNewsWire • 11/08/21
TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021GlobeNewsWire • 11/05/21
TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for Inhaled Formulation of Niclosamide to Treat COVID-19GlobeNewsWire • 10/28/21
TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral LoadGlobeNewsWire • 10/14/21
TFF Pharma's Inhaled Tacrolimus Powder Moves Closer To Phase 2 In Lung TransplantationBenzinga • 09/23/21
TFF Pharmaceuticals to Present at 23rd H.C. Wainwright Annual Global Investment ConferenceGlobeNewsWire • 09/08/21
TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/13/21
TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 08/12/21
Augmenta - TFF Pharma's COVID-19 Antibody Shows Preclinical Activity Against Delta VariantBenzinga • 07/29/21
Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387GlobeNewsWire • 07/29/21
TFF Pharmaceuticals to Participate in the BTIG Virtual Biotechnology ConferenceGlobeNewsWire • 07/28/21
TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its Phase 1 Clinical Trial of Tacrolimus Inhalation PowderGlobeNewsWire • 07/13/21
TFF Pharma, Augmenta Bioworks Select Lead Antibody Program To Develop For COVID-19Benzinga • 06/22/21
Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clinical Development Against COVID-19GlobeNewsWire • 06/22/21
TFF Pharmaceuticals to Participate in Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/25/21
TFF Pharmaceuticals' (TFFP) CEO Glenn Mattes on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21
TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire • 05/13/21
TFF Pharmaceuticals to Hold First Quarter 2021 Financial and Business Results Conference Call on May 13, 2021Business Wire • 05/04/21
TFF Pharmaceuticals Awarded Contract under DARPA's Next-Generation Personalized Protective Biosystems Program for U.S. WarfightersBusiness Wire • 04/13/21